The use of transgenic animals is a powerful and informative approach that has been successfully undertaken by Core B in previous cycles to study neurodegenerative diseases. Core B will provide Projects 1-4 with appropriately genotyped and aged mouse models of endosomal-autophagic-lysosomal system abnormalities observed in Alzheimer's disease (AD) and Down's syndrome (DS). Core B will also serve to identify novel animal models with these pathologies, and to generate novel crosses between these models, and either transgenic or knockout models that carry or lack genes expected to affect AD-related pathologies. Endosomal abnormalities are the earliest known pathology in AD, preceding AB deposition and, in human DS, can be detected in neurons even before birth. As a model of endosomal pathology we are using the Ts2 trisomic mouse, which we have identified as a model with pathologies similar to Ts65Dn mice yet with important breeding and transmission advantages. Among models used to examine endosomal and autophagic-lysosomal system pathologies are transgenic mice expressing human rab5, XI la, mutant presenilin 1, and knockout mice for presenilin 1. Models of either B-amyloidosis and amyloid p precursor protein (APP) overexpression or knockout are used to examine the effect of APP and APP metabolites on endocytosis and lysosomal system function. Additionally, in order to identify protective effects of cystatin C, which the core leader has shown to affect disease processes, mouse models with endosomal and autophagic-lysosomal system pathologies will be crossed with either transgenic or knockout mice for cystatin C. The Core Leader has extensive experience managing a large mouse colony with complex breeding schemes, and will be able to coordinate animal breeding, genotyping, and delivery to Projects 1-4.
The use of genetically engineered animals is a powerful and informative approach to study neurodegenerative diseases such as Alzheimer's disease (AD). This Core provides models to study age related progress of specific pathologies observed in the human AD, to identify genes and environmental factors that affect disease processes, and to develop potential therapies for AD.
|Li, Wei; Sultana, Nargis; Siraj, Nabeel et al. (2016) Autophagy dysfunction and regulatory cystatin C in macrophage death of atherosclerosis. J Cell Mol Med 20:1664-72|
|Mathews, Paul M; Levy, Efrat (2016) Cystatin C in aging and in Alzheimer's disease. Ageing Res Rev 32:38-50|
|Rosa, Elyse; Mahendram, Sujeivan; Ke, Yazi D et al. (2016) Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease. Neurobiol Aging 48:135-142|
|Colacurcio, Daniel J; Nixon, Ralph A (2016) Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res Rev 32:75-88|
|Strupp, Barbara J; Powers, Brian E; Velazquez, Ramon et al. (2016) Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease. Curr Alzheimer Res 13:97-106|
|Rao, Mala V; Campbell, Jabbar; Palaniappan, Arti et al. (2016) Calpastatin inhibits motor neuron death and increases survival of hSOD1(G93A) mice. J Neurochem 137:253-65|
|Tiernan, Chelsea T; Ginsberg, Stephen D; Guillozet-Bongaarts, Angela L et al. (2016) Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease. Neurobiol Aging 42:80-90|
|Kim, S; Sato, Y; Mohan, P S et al. (2016) Evidence that the rab5 effector APPL1 mediates APP-Î²CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease. Mol Psychiatry 21:707-16|
|Jiang, Ying; Rigoglioso, Andrew; Peterhoff, Corrinne M et al. (2016) Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. Neurobiol Aging 39:90-8|
|Morales-Corraliza, Jose; Wong, Harrison; Mazzella, Matthew J et al. (2016) Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-Î² Alterations in a Monkey Model of Type 1 Diabetes. J Neurosci 36:4248-58|
Showing the most recent 10 out of 141 publications